Skip to main content

Immunotherapy Study Targeting MAGE-A3 Protein Shows Responses

T cell-based immunotherapy targeting MAGE-A3 protein was found safe and showed early clinical responses in patients with a variety of metastatic cancers.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino